Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04453033 · ClinicalTrials.gov registry record · NA
DB RCT for Specialized Phototherapy in Parkinson's Disease.
A NA study of Parkinson Disease, sponsored by PhotoPharmics.
- Active
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT04453033: Active NA study of Parkinson Disease, sponsored by PhotoPharmics.
NCT04453033 is a NA study of Parkinson Disease that is active but no longer recruiting, run by PhotoPharmics. The registered enrollment target is 350 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04453033, a NA study of Parkinson Disease, is active but no longer recruiting, sponsored by PhotoPharmics.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pivotal study to determine whether light therapy can improve non-motor and motor function in Parkinson's disease, on top of current best medical treatment.
Primary Outcome
The Parkinson's Disease Questionnaire-39 (PDQ-39) is a patient-reported rating scale for quality of life in Parkinson's disease. Respondents affirm if they have experienced problems due to their disease using a five point scale from never (0 points) to always (4 points, or worse) in doing common activities. The PDQ-39 is comprised of 8 domains: mobility, emotion, activities of daily living, cognition, stigma, social support, communication, bodily discomfort. Total possible range of scores = 0 -
Conditions Studied
Interventions
- DEVICE Celeste Specialized Phototherapy Device
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-02-26 |
| Est. Completion | 2026-08-30 |
| Phase | NA |
What the registry record for NCT04453033 still lists
NCT04453033 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Celeste Specialized Phototherapy Device is the first listed.
NCT04453033 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04453033 about?
NCT04453033 is a clinical study titled "DB RCT for Specialized Phototherapy in Parkinson's Disease.". This is a pivotal study to determine whether light therapy can improve non-motor and motor function in Parkinson's disease, on top of current best medical treatment.
What is the current status of trial NCT04453033?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2024-02-26. Estimated completion is 2026-08-30.
What conditions does trial NCT04453033 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT04453033?
The interventions under investigation include: Celeste Specialized Phototherapy Device (DEVICE).
Who is sponsoring clinical trial NCT04453033?
This trial is sponsored by PhotoPharmics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04453033 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04453033's enrollment target sits among peer trials
350 31st of 297 higher than 267 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Neurophysiology of Reward Signaling in Parkinson's Disease
RECRUITING · NA
-
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
RECRUITING · NA
-
Rock Steady Boxing: A Community Based In Person Class
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI